dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
|
ACE inhibitors (eg, captopril) The risk of angioedema may be increased with coadministration of ACE inhibitors and everolimus. If an interaction is suspected, stop one or both drugs. Aprepitant Everolimus blood concentrations may be elevated, increasing the pharmacologic effects and risk of adverse reactions. If everolimus and aprepitant are coadministered, closely monitor everolimus blood concentrations and adjust the dose as needed. Cyclosporine Everolimus blood concentrations may be increased. Monitor everolimus concentrations and the clinical response of the patient when the cyclosporine dose is altered. Adjust the everolimus dose as needed. Digoxin Everolimus blood concentrations may be increased. Use with caution. Efavirenz Everolimus blood concentrations may be reduced, decreasing the efficacy. Closely monitor everolimus blood concentrations when efavirenz is started or stopped and adjust the everolimus dose as needed.
|